Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06830551
Recruiting Not applicable

The Effect of Cord Blood Serum Eyes Drops Administer in Patients With Severe Keratopathy Related to EGFR-I Treatment

NCT06830551 · tracked via the Priya Life Science Italy tracker
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase
Not applicable
Started
2023-09-12
Last updated
2025-02-17

Condition(s) studied

Dry Eye

Investigational drug(s) / intervention(s)

administration cord blood based eye drops, standardized to the deliver BDNF.

administration cord blood based eye drops, standardized to the deliver BDNF.: administration cord blood based eye drops customized to deliver epitelio tropic factors, incluiding EGF in EGFR blocked cells

Study summary

The study aim to evaluate the efficacy of cord blood eye drops in the healing of the damaged corneal epithelium.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * age over 18 years * oncology and advanced cancer patients who have EGFr mutation and who require treatment with antiEGFr drugs * signing of informed consent Exclusion Criteria: * Patients who are unable to store/administer the CSCO independently, or with the help of care-givers.

Primary outcome measure(s)

  • Corneal damage measured with National Eye Institute (NEI) score — one week before the start of treatment and thirty days after the end of treatment.
    Evaluation of the effect of cord blood eye drops administration on the variation of corneal damage in patients with severe keratopathy

Trial sites (1)

FacilityCityRegionStatus
IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy Recruiting

More IRCCS Azienda Ospedaliero-Universitaria di Bologna trials in Italy

The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients Recruiting
Comparison of Cervical Cerclage by Vaginal and by Laparoscopic Transabdominal Routes in the Periconceptional Period Recruiting
Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH Recruiting
Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers Recruiting
Epidemiology of Acute Otomastoiditis in Pediatric Age Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06830551 on ClinicalTrials.gov ↗ ← All trials in Italy